Repligen Co. (NASDAQ:RGEN) has been assigned an average recommendation of “Buy” from the eleven analysts that are currently covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 12-month target price among brokers that have covered the stock in the last year is $44.57.

A number of research analysts have recently commented on RGEN shares. JPMorgan Chase & Co. started coverage on Repligen in a report on Tuesday, December 5th. They set an “overweight” rating and a $42.00 price objective on the stock. Citigroup started coverage on Repligen in a report on Friday, December 8th. They set a “buy” rating and a $45.00 price objective on the stock. BidaskClub raised Repligen from a “hold” rating to a “buy” rating in a report on Saturday, December 30th. Zacks Investment Research raised Repligen from a “sell” rating to a “hold” rating in a report on Thursday, January 11th. Finally, TheStreet raised Repligen from a “c” rating to a “b-” rating in a report on Tuesday, March 13th.

How to Become a New Pot Stock Millionaire

Repligen (NASDAQ RGEN) opened at $36.75 on Friday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 8.08 and a current ratio of 9.63. The company has a market capitalization of $1,590.98, a PE ratio of 51.76, a PEG ratio of 2.44 and a beta of 0.94. Repligen has a fifty-two week low of $29.56 and a fifty-two week high of $46.81.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Thursday, February 22nd. The biotechnology company reported $0.20 EPS for the quarter, beating the Zacks’ consensus estimate of $0.12 by $0.08. The business had revenue of $41.60 million for the quarter, compared to analyst estimates of $41.13 million. Repligen had a return on equity of 7.08% and a net margin of 20.08%. The firm’s revenue for the quarter was up 62.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.08 EPS. analysts expect that Repligen will post 0.7 earnings per share for the current year.

In other Repligen news, Director Thomas F. Ryan, Jr. sold 4,696 shares of the firm’s stock in a transaction that occurred on Thursday, March 8th. The stock was sold at an average price of $36.16, for a total value of $169,807.36. Following the sale, the director now owns 9,700 shares of the company’s stock, valued at approximately $350,752. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Anthony Hunt sold 8,970 shares of the firm’s stock in a transaction that occurred on Monday, January 22nd. The shares were sold at an average price of $35.95, for a total value of $322,471.50. Following the completion of the sale, the chief executive officer now directly owns 83,613 shares in the company, valued at approximately $3,005,887.35. The disclosure for this sale can be found here. Company insiders own 1.50% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. First Manhattan Co. grew its holdings in Repligen by 16.7% in the 4th quarter. First Manhattan Co. now owns 10,500 shares of the biotechnology company’s stock valued at $380,000 after buying an additional 1,500 shares during the last quarter. California Public Employees Retirement System grew its holdings in Repligen by 1.6% in the 3rd quarter. California Public Employees Retirement System now owns 122,548 shares of the biotechnology company’s stock valued at $4,696,000 after buying an additional 1,948 shares during the last quarter. Nationwide Fund Advisors grew its holdings in Repligen by 2.4% in the 3rd quarter. Nationwide Fund Advisors now owns 84,480 shares of the biotechnology company’s stock valued at $3,237,000 after buying an additional 1,979 shares during the last quarter. Cornerstone Capital Management Holdings LLC. grew its holdings in Repligen by 12.3% in the 4th quarter. Cornerstone Capital Management Holdings LLC. now owns 18,206 shares of the biotechnology company’s stock valued at $660,000 after buying an additional 2,000 shares during the last quarter. Finally, Swiss National Bank grew its holdings in Repligen by 5.3% in the 4th quarter. Swiss National Bank now owns 63,700 shares of the biotechnology company’s stock valued at $2,311,000 after buying an additional 3,200 shares during the last quarter. 87.60% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This piece of content was reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/repligen-co-rgen-receives-average-rating-of-buy-from-brokerages/1941564.html.

Repligen Company Profile

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Analyst Recommendations for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.